Satellos Bioscience Company Description

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia.

The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.

It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease.

The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia.

Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc.

Country	Canada
Founded	2018
Industry	Biotechnology
Sector	Healthcare
Employees	17
CEO	Francis Gleeson

Contact Details

Address: Royal Bank Plaza Toronto, Ontario M5J 2J1 Canada
Website	satellos.com

Stock Details

Ticker Symbol	MSCL
Exchange	Toronto Stock Exchange
Fiscal Year	January - December
Reporting Currency	CAD
ISIN Number	CA80401L3083
SIC Code	2834

Key Executives

Name	Position
Francis Gleeson B.B.A. M.B.A	Co-Founder, Chief Executive Officer, President and Director
Elizabeth Williams C.A., CPA	Chief Financial Officer and Corporate Secretary
Dr. Philip Lambert M.A., Ph.D.	Chief Scientific Officer
William Wasyl Jarosz	Executive Director
Warren Whitehead C.M.A., CPA	Head of Corporate Strategy
Dr. Michael A. Rudnicki Ph.D.	Co-Founder and Chief Discovery Officer
J. Robert Hall CFA	Senior Vice President of Finance and Administration
Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A., CA, CPA	Strategic Advisor
Desiree Chan	Chief of Staff
Courtney Wells	Senior Vice President of Clinical Development Operations